drugset / Trial / NCT03114540
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild (Child-Pugh A), moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment disease and healthy subjects with normal hepatic function.
Timeline
- Start
- 2017-03-17
- Primary completion
- 2018-02-28
- Completion
- 2018-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voxelotor | Small molecule | — | Oral |
Indications
No indication recorded.